RALEIGH, N.C., April 18 /PRNewswire/ -- Voyager Pharmaceutical Corporation will present information about its scientific and clinical approach for the treatment of Alzheimer’s disease at the 9th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy, the company announced Tuesday.
Dr. Brian Reynolds, director of medical and scientific information at Voyager Pharmaceutical Corporation, will discuss the stabilization of cognitive decline in AD following treatment with leuprolide acetate. Reynolds is among the 125 leading physicians and scientists invited to speak at the conference.
The 9th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy focuses on Alzheimer’s disease treatment and dementia research and will be held April 19 - 22 in Geneva, Switzerland.
Reynolds’ presentation will take place in Room B of the International Conference Centre in Geneva (CICG) on April 22. A total of more than 100 sessions will be presented during the four-day symposium, and nearly 900 specialists are expected to attend the international gathering.
About the Symposium
The 9th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy was established by Ezio Giacobini, M.D., Ph.D., and professor emeritus of the Southern Illinois University School of Medicine in Springfield, Illinois, U.S.A. and faculty member at the University of Geneva in Switzerland. Giacobini organized this year’s conference with Dr. Jean-Pierre Michel, professor and chair of rehabilitation and geriatrics at the University of Geneva Medical School in Switzerland.
Symposium presentations will include historical data reflecting the progress of science and the results of various treatments of Alzheimer’s disease that have been studied and tested during the past 20 years.
The International Geneva/Springfield Symposium on the Advances in Alzheimer Therapy was first held in 1988 in Springfield, Illinois. The conference is held every other year.
Conference information is posted online at http://www.siumed.edu/cme/html/alzheimer.html.
About Voyager Pharmaceutical Corporation
Voyager Pharmaceutical Corporation is a biopharmaceutical company focused on developing drugs for diseases associated with aging and development. Voyager’s scientific approach is based on the observation that many diseases of aging may be caused by changes in human reproductive hormone levels that are characteristic of the aging process. Voyager’s most advanced product candidate is VP4896, a proprietary, small, biodegradable implant that is comprised of leuprolide acetate and a polymer, in Phase III clinical development for mild to moderate Alzheimer’s disease. VP4896 decreases the amount of luteinizing hormone (LH) released by the pituitary gland which, Voyager believes, may decrease or slow the progression of Alzheimer’s disease.
Voyager was founded in 2001 and is headquartered in Raleigh, N.C. For more information go to www.voyagerpharma.com.
Contact Information:
Patrick S. Smith, President and CEO
(919) 846-4880
Voyager Pharmaceutical Corporation
CONTACT: Patrick S. Smith, President and CEO, +1-919-846-4880
